The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Drug-induced Liver Injury Due to Medications for Alcohol Use Disorder: Results From the DILIN Prospective Study
Abstract
Objectives: Concerns about drug-induced liver injury (DILI) may deter physicians from prescribing medications for alcohol use disorder (MAUD). We aim to explore DILI due to MAUD in Drug-Induced Liver Injury Network (DILIN) prospective study. Methods: High-confidence DILI cases (ie, definite, highly likely, or probable) due to MAUD in DILIN prospective study (2004–2024) were included. Demographic, clinical, laboratory data, and 6-month outcomes were analyzed. HLA allele frequency (AF) of disulfiram cases was compared to matched controls with DILI due to non-MAUD (DILI controls). Results: Among 1975 high-confidence cases, 13 were attributed to MAUD (11 disulfiram; 1 naltrexone and 1 baclofen; and none from acamprosate). Median age was 45 years, with 77% female and 85% White. All had hepatocellular injury. In disulfiram group, the median time for DILI occurrence was 34 days. Eight patients developed jaundice, with 3 fatal or near-fatal cases (2 liver transplantation and 1 liver-related death). Five (71%) patients with severe or fatal disulfiram DILI had underlying liver disease. AF for HLA-C*01:02 (OR, 6.29; P = 0.02) and DRB1*09:01 (OR, 10.16; P = 0.02) were significantly higher in disulfiram cases than in DILI controls. DILI from baclofen and naltrexone was mild and self-limited with no chronic DILI. Conclusions: Disulfiram is the leading cause of DILI among MAUD and is most common in women. Disulfiram can cause severe DILI and is associated with HLA-C*01:02 and DRB1*09:01. Baclofen and naltrexone can cause mild to moderate self-limited DILI. There were no cases of acamprosate. These findings suggest DILI due to MAUD are less frequent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a case series of hepatotoxicity attributed to AUD medications, disulfiram was most commonly implicated, with only 1 case attributed to naltrexone despite its widespread and increasing use. 62”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griswold, M. G., Fullman, N., Hawley, C., Arian, N., Zimsen, S. R. M., Tymeson, H. D., Venkateswaran, V., Tapp, A. D., Forouzanfar, M. H., Salama, J. S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31310-2 · Cited by 3,524
Self-citationGlobal burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.006 · Cited by 925
Self-citationAddolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D'Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 685
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Self-citationAlcohol-Related Deaths During the COVID-19 Pandemic
White, A. M., Castle, I.-J. P., Powell, P. A., Hingson, R. W., & Koob, G. F. (2022) · JAMA · doi:10.1001/jama.2022.4308 · Cited by 369
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023) · JAMA · doi:10.1001/jama.2023.19761 · Cited by 285
Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis
Rogal, S. S., Youk, A. O., Zhang, H., Gellad, W. F., Fine, M. J., Good, C. B., Chartier, M., DiMartini, A. F., Morgan, T. R. M., Bataller, R. A., et al. (2019) · Hepatology · doi:10.1002/hep.31042 · Cited by 233
Alcohol Consumption: Medical Implications, the Liver and Beyond
Meza, V., Arnold, J., Díaz, L. A., Ayala-Valverde, M., Idalsoaga, F. J., Ayares, G., Devuni, D., & Arab, J. P. (2022) · Alcohol and Alcoholism · doi:10.1093/alcalc/agac013 · Cited by 163
Esser, M. B., Leung, G., Sherk, A., Bohm, M. K., Liu, Y., Lu, H., & Naimi, T. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.39485 · Cited by 147
Vannier, A., Shay, J. E. S., Fomin, V., Patel, S. J., Schaefer, E. A. K., Goodman, R. P., & Luther, J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.13014 · Cited by 137
Sex and Gender Effects in Recovery From Alcohol Use Disorder
Holzhauer, C. G. (2020) · Alcohol research · doi:10.35946/arcr.v40.3.03 · Cited by 131
Clinical characteristics and prognostic markers in disulfiram-induced liver injury
Bjornsson, E. S., Nordlinder, H., & Olsson, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.016 · Cited by 83
Rabiee, A., Mahmud, N., Falker, C. G., García–Tsao, G., Taddei, T. H., & Kaplan, D. E. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000093 · Cited by 78
Li, Y., Phillips, E. J., Dellinger, A., Nicoletti, P., Schutte, R., Li, D., Ostrov, D. A., Fontana, R. J., Watkins, P. B., Stolz, A., et al. (2021) · Hepatology · doi:10.1002/hep.31258 · Cited by 76
Self-citationNaltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease
Ayyala-Somayajula, D., Bottyan, T., Tien, C., Pimienta, M., Yoo, J. C., Stager, K., González, J. L., Stolz, A., Dodge, J. L., Terrault, N. A., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2080 · Cited by 64
Sinclair, J., Chambers, S. E., Shiles, C. J., & Baldwin, D. S. (2016) · Drug Safety · doi:10.1007/s40264-016-0416-y · Cited by 62
Disulfiram-induced hepatitis. Report of four cases and review of the literature
Forns, X., Caballería, J., Bruguera, M., Salmerón, J. M., Vilella, À., Mas, A., Parés, A. R., & Rodés, J. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80249-1 · Cited by 61
Yamini, D., Lee, S. H., Avanesyan, A., et al. (2014) · Alcohol and Alcoholism · doi:10.1093/alcalc/agu028 · Cited by 51
Gratacós‐Ginès, J., Bruguera, P., Pérez-Guasch, M., López-Lazcano, A., Borràs, R., Hernández-Évole, H., Pons-Cabrera, M. T., Lligoña, A., Bataller, R. A., Ginès, P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000570 · Cited by 39
Chalasani, N., Bonkovsky, H. L., Stine, J. G., Gu, J., Barnhart, H. X., Jacobsen, E. I., Bjornsson, E. S., Fontana, R. J., Kleiner, D. E., & Hoofnagle, J. H. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.013 · Cited by 36
Self-citationTyson, L. D., Cheng, A., Kelleher, C., Strathie, K., Lovendoski, J., Habtemariam, Z., & Lewis, H. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002304 · Cited by 32
Survey of Addiction Specialists’ Use of Medications to Treat Alcohol Use Disorder
Ehrie, J., Hartwell, E. E., Morris, P. E., Mark, T. L., & Kranzler, H. R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00047 · Cited by 29
Morris, S. J., Kanner, R., Chiprut, R. O., & Schiff, E. R. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)93772-1 · Cited by 23
Simon, N., Franchitto, N., & Rolland, B. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00485 · Cited by 20
Baclofen-induced acute hepatitis in alcohol-dependent patient
Macaigne, G., Champagnon, N., Harnois, F., et al. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.01.019 · Cited by 15
Duan, F., Zhai, H., Liu, C., Chang, C., Song, S., Li, J., Cheng, J., & Yang, S. T. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.06.042 · Cited by 14
Green, E. W., Byers, I. S., & Deutsch‐Link, S. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.017 · Cited by 14
Baekdal, M., Ytting, H., & Kjær, M. S. (2016) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2016.1267790 · Cited by 13
Disulfiram hepatotoxicity: Report of three cases
Celada-Sendino, M., Álvarez‐Navascués, C., & Rodríguez, M. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.04.011 · Cited by 3
Research works printed but not linked: 3
- Teschke, 2024, Human leucocyte antigen genetics in idiosyncratic drug-induced liver injury with evidence based on the Roussel Uclaf causality assessment method, Medicines (Basel), 11
- Gonzalez-Galarza, 2020, Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools, Nucleic Acids Res, 48, D783
- Teschke, 2018, Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method, Expert Opin Drug Metab Toxicol, 14, 1169
Cited by
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Self-citation
Metadata
- Authors
- Gopalakrishna, H., Ghabril, M., Gu, J., Li, Y. J., Fontana, R. J., Kleiner, D. E., Koh, C., Chalasani, N., & for the Drug-Induced Liver Injury Network
- Venue
- Journal of Addiction Medicine
- Published
- 2024-12-09
- Volume
- 19
- Issue
- 3
- Pages
- 314-321
- ISSN
- 1935-3227
- 1932-0620
- PMC
- PMC12133418
- Cited by
- 12
- References
- 31
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
